Zhejiang Orient Gene Biotech Co., Ltd. (688298. sh), established December 2005, was listed on Sci-Tech innovation board (STAR Market）of Shanghai Stock Exchange (SSE) on February 6th, 2020. Orient Gene is a high-tech biomedical technology company registered in the city of Anji, Huzhou. With registered capital 12 billion yuan, Orient Gene specializes in the R&D, production and sales of in vitro diagnostic products. Orient Gene features an expansive and developmental product portfolio focusing on Point of Care Tests (POCT), molecular diagnostics, liquid biochips, biological raw materials and instruments. It further divides products into five key categories: Toxicology, Infectious Disease, Pregnancy and Fertility, Tumor Marker and Cardiac Marker. Among them, Toxicology and Infectious Disease tests are its core products. Orient Gene's in-house manufacturing process involves reagents and materials generated by its subsidiaries.
As one of the most internationally certified IVD companies in China, Orient Gene has an extensive customer base that covers more than 100 countries. Currently it possesses 65 trademark registrations, 95 patents, 67 CFDA product and filing certificates, 34 USFDA 510(k) clearances, 225 CE certificates, 68 Health Canada Medical Device Licenses and 4 licenses from Mexico's COFEPRIS. Among these numerous registrations, our most notable is the acquisition of the CE List A certificate for HIV and Hepatitis C (HCV) testing. Broad acknowledgement by regulatory institutions in combination with excellent product performance, align our brand with the expectations of key distribution channels such as: McKesson, Dollar Tree and other Fortune 500 companies.
Due to our efforts in academia and R&D, the statuses of ‘Provincial High-tech Enterprise Research and Development Center for IVD’ and ‘Academician expert workstation’ were granted to Orient Gene. It has been recognized by the Ministry of Science and Technology of China, Zhejiang Provincial Department of Science and Technology, Huzhou Municipal People's Government, WHO, Bill & Melinda Gates Foundation, and other institutions. Orient Gene's Malaria (pf/pan) and Malaria (pf) tests have passed the fifth and seventh rounds of evaluation by the WHO.
Orient Gene strives to remain on the forefront of in vitro diagnostic technology. In pursuit of researching the latest biological raw materials for toxicology, Orient Gene established an antigen R&D subsidiary in Canada. In conjunction with antigen research overseas, domestic antibody production in Qingdao supports our global marketplace. Orient Gene continues to invest and expand its rising strategic platforms of biological raw materials, instruments, molecular diagnosis and liquid biochip technologies. Over 30 antigens and antibodies have been developed independently, of which more than 10 have been used in Orient Gene's POCT reagents. Its instrument developer, Changjian, has launched six IVD instruments, where one of them has been commercialized and another is undergoing registration. Orient Gene's Real-Time PCR reagent kits for molecular diagnosis have four NMPA certificates, and ten have acquired a Confirmation Letter from the EU. Our latest venture, liquid biochip technology, will provide multiplexing test kits with various targets focusing on tumor markers, allergen screening and cardiac markers.
| Full name | Zhejiang Orient Gene Biotech Co., Ltd |
|---|---|
| Abbreviations | Orient Biotech (Orient Gene) |
| Code | 688298 |
| Founded | 2005-12-01 |
| Listing | 2020-02-05 |
| Domicile | Anji, Zhejiang, China |
| Website | www.orientgene.com |
| zqb@orientgene.com | |
| STAR Theme | Biomedicine |
| CSRCSector | Biomedicine Manufacturing(C27) |
| Has weighted voting rights structure? | N |
| 2018 | 2017 | 2016 | |
|---|---|---|---|
| Earnings Per Share | 0.73 | 0.37 | |
| R&D expenditure as a % of operating revenue | 6.52% | 5.49% | 5.08% |
| Operating Revenue | 285.89 million | 224.24 million | 182.26 million |
| Net Income | 63.96 million | 32.71 million | 35.63 million |
| 2018 | 2017 | 2016 | |
|---|---|---|---|
| Operating Revenue | 285.89 | 224.24 | 182.26 |
| Operating Costs | 146.75 | 116.33 | 94.62 |
| Operating Income | 75.16 | 37.22 | 40.32 |
| Pretax Income | 77.00 | 39.82 | 43.80 |
| Income Tax | 13.04 | 7.11 | 8.17 |
| Net Income | 63.96 | 32.71 | 35.63 |
| 2018 | 2017 | 2016 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 243.72 | 179.73 | 168.85 |
| Non-current Assets-Total | 93.93 | 79.59 | 72.15 |
| Total Assets | 337.65 | 259.32 | 241.00 |
| Liabilities | |||
| Current Liabilities-Total | 121.26 | 116.50 | 137.08 |
| Non-current Liabilities-Total | 8.36 | 4.70 | 5.20 |
| Total Liabilities | 129.62 | 121.20 | 142.28 |
| Stockholder's Equity | |||
| Share Capital | 118.39 | 117.53 | 110.65 |
| Retained Profits | 82.64 | 15.96 | -11.93 |
| Minority Interests | 7.00 | 4.63 | |
| Total Owners' Equity | 208.03 | 138.12 | 98.72 |
| 2018 | 2017 | 2016 | |
|---|---|---|---|
| Net Cash Flows-Operating | 44.33 | 33.54 | 11.81 |
| Net Cash Flows-Investing | -18.75 | -15.76 | 85.45 |
| Net Cash Flows-Financing | -5.72 | -18.22 | -28.36 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 安吉福浪莱进出口贸易有限公司 | 23.40 | 26.00% |
| FANGS HOLDINGS LLC | 22.50 | 25.00% |
| Shanghai XiangheyongAn Equity Investment Partnership Enterprise (LP) | 14.24 | 15.82% |
| 安吉涌威投资合伙企业（有限合伙） | 12.37 | 13.75% |
| 浙江永石股权投资合伙企业（有限合伙） | 8.27 | 9.19% |
| 宁波梅山保税港区君澜和美股权投资合伙企业（有限合伙） | 2.25 | 2.50% |
| Shanghai Yongchuanghuaxing Investment Partnership Enterprise (LP) | 2.14 | 2.38% |
| 杭州乘天投资管理合伙企业（有限合伙） | 1.80 | 2.00% |
| 安吉裕威竹制品合伙企业（有限合伙） | 1.10 | 1.23% |
| Lianyungang Yongcheng Equity Investment Partnership Enterprise (LP) | 1.07 | 1.19% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.